Mostafa S K Tawfeek1, Doaa M Raafat1, Khaled Saad2, Naglaa K Idriss3, Sherif Sayed4, Doaa A Fouad5, Amira A El-Houfey6. 1. Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt. 2. Associate Professor of Pediatrics, Faculty of Medicine, University of Assiut, Assiut 71516, Egypt khaled.ali@med.au.edu.eg ksaad8@yahoo.com. 3. Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt. 4. Department of Anesthesiology, Faculty of Medicine, Assiut University, Assiut, Egypt. 5. Department of Cardiology, Faculty of Medicine, Assiut University, Assiut, Egypt. 6. Department of Community Health Nursing, Assiut University, Assiut, Egypt.
Abstract
INTRODUCTION: Data about plasma levels of neutrophil gelatinase-associated lipocalin (NGAL) in children with heart failure (HF) are very limited. NGAL is used widely as a biomarker for the diagnosis of renal injury in numerous clinical studies. The aim of this study is to investigate the plasma NGAL in children with HF caused by idiopathic dilated cardiomyopathy (IDCM) and its relation to the severity of HF. MATERIAL AND METHODS: In a case-control study, 30 nondiabetic children, aged -16 years (all have IDCM) recruited from the pediatric department of our institute together with 30 healthy children were prospectively enrolled in this study. Patients underwent a detailed history taking, clinical examination, New York Heart Association (NYHA) class assessment and echocardiographic evaluation. Plasma levels of NGAL were measured by enzyme-linked immunosorbent assay. RESULTS: Plasma levels of NGAL were significantly higher in children with HF compared with healthy controls (mean: 290.97 versus 144.33, p < 0.0001). The relationship between NGAL and the severity of HF was investigated. However, we did not find any statistically significant relationship between plasma NGAL levels and indices of myocardial function. CONCLUSIONS: NGAL levels were significantly increased in children with HF caused by IDCM. However, there was no significant relationship between plasma NGAL levels and indices of myocardial function. Future multicenter clinical studies in a large population addressing the natural course of NGAL in HF and its potential as a treatment target are needed in the near future.
INTRODUCTION: Data about plasma levels of neutrophil gelatinase-associated lipocalin (NGAL) in children with heart failure (HF) are very limited. NGAL is used widely as a biomarker for the diagnosis of renal injury in numerous clinical studies. The aim of this study is to investigate the plasma NGAL in children with HF caused by idiopathic dilated cardiomyopathy (IDCM) and its relation to the severity of HF. MATERIAL AND METHODS: In a case-control study, 30 nondiabetic children, aged -16 years (all have IDCM) recruited from the pediatric department of our institute together with 30 healthy children were prospectively enrolled in this study. Patients underwent a detailed history taking, clinical examination, New York Heart Association (NYHA) class assessment and echocardiographic evaluation. Plasma levels of NGAL were measured by enzyme-linked immunosorbent assay. RESULTS: Plasma levels of NGAL were significantly higher in children with HF compared with healthy controls (mean: 290.97 versus 144.33, p < 0.0001). The relationship between NGAL and the severity of HF was investigated. However, we did not find any statistically significant relationship between plasma NGAL levels and indices of myocardial function. CONCLUSIONS:NGAL levels were significantly increased in children with HF caused by IDCM. However, there was no significant relationship between plasma NGAL levels and indices of myocardial function. Future multicenter clinical studies in a large population addressing the natural course of NGAL in HF and its potential as a treatment target are needed in the near future.
Authors: Tobias Breidthardt; Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Beatrice Drexler; Theresia Klima; Catharina Balmelli; Philipp Schuetz; Philip Haaf; Michael Schärer; Michael Tamm; Beat Müller; Christian Müller Journal: Am J Med Date: 2012-02 Impact factor: 4.965
Authors: Arne Yndestad; Jan Kristian Damås; Erik Øie; Thor Ueland; Lars Gullestad; Pål Aukrust Journal: Curr Cardiol Rep Date: 2007-05 Impact factor: 2.931
Authors: Arne Yndestad; Linn Landrø; Thor Ueland; Christen P Dahl; Trude H Flo; Leif Erik Vinge; Terje Espevik; Stig S Frøland; Cathrine Husberg; Geir Christensen; Kenneth Dickstein; John Kjekshus; Erik Øie; Lars Gullestad; Pål Aukrust Journal: Eur Heart J Date: 2009-03-26 Impact factor: 29.983
Authors: Vincent M van Deursen; Kevin Damman; Adriaan A Voors; Martje H van der Wal; Tiny Jaarsma; Dirk J van Veldhuisen; Hans L Hillege Journal: Circ Heart Fail Date: 2013-12-17 Impact factor: 8.790